X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs CADILA HEALTHCARE - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. CADILA HEALTHCARE WOCKHARDT LTD./
CADILA HEALTHCARE
 
P/E (TTM) x -23.9 20.1 - View Chart
P/BV x 2.4 4.8 50.8% View Chart
Dividend Yield % 0.0 0.9 0.2%  

Financials

 WOCKHARDT LTD.   CADILA HEALTHCARE
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
CADILA HEALTHCARE
Mar-18
WOCKHARDT LTD./
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,012558 181.4%   
Low Rs532362 147.0%   
Sales per share (Unadj.) Rs355.9116.3 306.0%  
Earnings per share (Unadj.) Rs-60.317.9 -337.4%  
Cash flow per share (Unadj.) Rs-46.823.1 -202.2%  
Dividends per share (Unadj.) Rs0.013.50 0.3%  
Dividend yield (eoy) %00.8 0.2%  
Book value per share (Unadj.) Rs257.885.4 301.8%  
Shares outstanding (eoy) m110.631,023.74 10.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.0 54.9%   
Avg P/E ratio x-12.825.7 -49.8%  
P/CF ratio (eoy) x-16.519.9 -83.0%  
Price / Book Value ratio x3.05.4 55.6%  
Dividend payout %019.6 -0.1%   
Avg Mkt Cap Rs m85,379470,664 18.1%   
No. of employees `0006.311.8 52.9%   
Total wages/salary Rs m9,37118,545 50.5%   
Avg. sales/employee Rs Th6,295.010,072.7 62.5%   
Avg. wages/employee Rs Th1,498.31,569.1 95.5%   
Avg. net profit/employee Rs Th-1,066.31,547.7 -68.9%   
INCOME DATA
Net Sales Rs m39,369119,049 33.1%  
Other income Rs m1,2021,132 106.2%   
Total revenues Rs m40,571120,181 33.8%   
Gross profit Rs m1828,475 0.1%  
Depreciation Rs m1,4955,388 27.8%   
Interest Rs m2,555911 280.5%   
Profit before tax Rs m-2,83023,308 -12.1%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2575,644 4.6%   
Profit after tax Rs m-6,66918,292 -36.5%  
Gross profit margin %023.9 0.2%  
Effective tax rate %-9.124.2 -37.5%   
Net profit margin %-16.915.4 -110.2%  
BALANCE SHEET DATA
Current assets Rs m33,79682,005 41.2%   
Current liabilities Rs m26,91760,720 44.3%   
Net working cap to sales %17.517.9 97.7%  
Current ratio x1.31.4 93.0%  
Inventory Days Days7973 108.5%  
Debtors Days Days8998 90.8%  
Net fixed assets Rs m39,66483,703 47.4%   
Share capital Rs m5531,024 54.0%   
"Free" reserves Rs m27,96886,421 32.4%   
Net worth Rs m28,52287,445 32.6%   
Long term debt Rs m21,73125,551 85.0%   
Total assets Rs m81,620180,653 45.2%  
Interest coverage x-0.126.6 -0.4%   
Debt to equity ratio x0.80.3 260.8%  
Sales to assets ratio x0.50.7 73.2%   
Return on assets %-5.010.6 -47.4%  
Return on equity %-23.420.9 -111.8%  
Return on capital %-7.722.0 -34.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80742,683 23.0%   
Fx outflow Rs m1,78911,242 15.9%   
Net fx Rs m8,01931,441 25.5%   
CASH FLOW
From Operations Rs m6849,193 7.4%  
From Investments Rs m6,302-9,737 -64.7%  
From Financial Activity Rs m-7,695515 -1,494.1%  
Net Cashflow Rs m-664-29 2,289.7%  

Share Holding

Indian Promoters % 74.5 74.8 99.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 8.3 27.7%  
FIIs % 7.7 5.9 130.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 11.0 140.0%  
Shareholders   67,757 44,069 153.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Sep 19, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS